Skip to main content
. 2020 Aug 21;9(9):1940. doi: 10.3390/cells9091940

Table 1.

Summary of the compounds used in the present study and detailed information about their actions, dosage and reference for dose selection.

Compound Target/Action Commercial Source Dose (Ref No)
compound C (CC) AMPK inhibition P5499; Sigma Aldrich (St Louis, MO, USA) 10 μg [4,18]
etomoxir (ETOM) CPT1 inhibition E1905; Sigma Aldrich (St Louis, MO, USA) 10 μg [13,18]
rapamycin (RAPA) mTOR inhibition 553210; Calbiochem (San Diego, CA, USA) 50 μg [15,20]